Stock Ratings / Materials / CDXS / insiders

ACNT (31) LODE (21) AMTX (28) LTBR (28) ⌘ Pro Terminal →

Codexis Inc. (CDXS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is CDXS trading relative to its 50-day, 200-day, and 52-week technical levels?

CDXS last traded at $1.19 (-2.46% on volume of 789,474 shares), positioning the stock -14.39% below its 50-day simple moving average ($1.39) and -34.25% below its 200-day simple moving average ($1.81). Across its 52-week range of $0.96 to $2.98, CDXS sits at the 11.4% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.04 to $1.34).

Q: Are CDXS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CDXS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.19 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.18

Codexis Inc. (CDXS) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $133.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CDXS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CDXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Codexis Inc. (NASDAQ: CDXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $1.19 (-2.46% 1D, market cap $133.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 4/20, and SEC Balance-Sheet Forensics 3/20. Across 270 tracked Materials issuers, CDXS ranks #260 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CDXS compare to ACNT and LODE in the Materials sector?

▼

Within the Materials sector (Major Chemicals), CDXS carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 86.7%, and ROIC of -35.0%. By comparison, ACNT (Ascent Industries Co.) holds a E grade (31/100 RQD, P/E 143.4x, ROIC -18.9%, cap $124.3M) and LODE (Comstock Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -33.3%, cap $122.3M). Among the 5-stock peer group, ACNT leads on earnings multiple (143.4x) while LTBR leads on capital efficiency (-9.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CDXS?

▼

Per CDXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001200375), Codexis Inc. generated $70.4M in revenue (+18.6% YoY), -$44.0M in net income, and -$23.8M in free cash flow against $147.8M in total assets and $40.1M in total debt. Key quantitative strengths: Established market leader in Materials with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.18 (-0.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CDXS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (23/100 Composite)

🔍 WHY CDXS SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (35% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 86.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.41-6.4% Next Q

Q2 (-2Q)

Grade E$1.32-1.5% Next Q

Q3 (-1Q)

Grade E$1.30-8.5% Next Q

Current

Grade E$1.19-11.1% Hist 90D α

Trajectory: E (31) → E (23)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CDXS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CDXS currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Materials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.39) and Max Pain ($1.25) forces dealer call-delta covering toward $3.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CDXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CDXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 23%NO 77%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CDXS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CDXS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CDXS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CDXS)

✓Walkthrough of CDXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CDXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.59%⚡ TESTING RESISTANCE

2026-11-02O $1.26H $1.26L $1.19C $1.19VOL 917.3K

RES: $1.26SUP: $1.18SMA50: $1.39SMA200: $1.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CDXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CDXS Butterfly Map → + Track CDXS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +18.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CDXS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CDXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CDXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CDXS)

Materials Rank #260 of 270 ⚔️ ACNT vs CDXS Full Matrix →

1. Head-to-Head Materials Peer Comparison (CDXS vs. ACNT, LODE, AMTX, LTBR)

Industry: Major Chemicals (67 Tracked Issuers)

Across 270 tracked Materials securities in the Roarable RQD universe, Codexis Inc. (CDXS) ranks #260 by composite RQD confidence (23/100, grade E) and #222 by equity capitalization ($133.6M). Within this direct 5-issuer industry benchmark cohort, ACNT leads on earnings valuation at 143.4x trailing P/E, while LTBR leads on capital efficiency and profitability with -9.1% ROIC and — gross margin. ACNT currently holds the highest overall quantitative score in the immediate peer group at 31/100 (E) compared with CDXS at 23/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CDXS ACTIVE Codexis Inc.	E	23/100	—	86.7%	-35.0%	-2.46%	$133.6M	Benchmark Subject
ACNT Ascent Industries Co.	E	31/100	143.4x	23.0%	-18.9%	-0.36%	$124.3M	/acnt-vs-cdxs →
LODE Comstock Inc.	E	21/100	—	-30.0%	-33.3%	-12.42%	$122.3M	/lode-vs-cdxs →
AMTX Aemetis Inc.	E	28/100	—	-0.4%	-35.0%	-3.10%	$93.1M	/amtx-vs-cdxs →
LTBR Lightbridge Corporation	E	28/100	—	—	-9.1%	-5.93%	$202.3M	/ltbr-vs-cdxs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001200375

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Codexis Inc. (CDXS) reported GAAP revenue of $70.4M (+18.6% vs. FY2024 revenue of $59.3M , and +0.3% cumulative change since FY2023) , GAAP net income of -$44.0M, operating cash flow of -$19.4M, and free cash flow of -$23.8M (+55.6% YoY). On the balance sheet, CDXS closed FY2025 with $147.8M in total assets against $40.1M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$70.4M	-$44.0M	-$19.4M	-$23.8M	$147.8M	$40.1M
FY2024 (FY)	2024-12-31	$59.3M	-$65.3M	-$49.4M	-$53.7M	$149.0M	$28.9M
FY2023 (FY)	2023-12-31	$70.1M	-$76.2M	-$52.6M	-$52.6M	—	—

3. CDXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CDXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CDXS compare to ACNT and LODE in the Materials sector?

What are the biggest fundamental strengths and SEC risk factors for CDXS?

Where is CDXS trading relative to its 50-day, 200-day, and 52-week technical levels?

CDXS last traded at $1.19 (-2.46% on volume of 789,474 shares), positioning the stock -14.39% below its 50-day simple moving average ($1.39) and -34.25% below its 200-day simple moving average ($1.81). Across its 52-week range of $0.96 to $2.98, CDXS sits at the 11.4% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.04 to $1.34).

CDXS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CDXS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CDXS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CDXS RQD Cockpit CDXS 12M Forecast CDXS Earnings & Move CDXS Dividends & DRIP CDXS Insiders & 13F CDXS Whale Options CDXS Profit Sankey CDXS News & Why

ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CDXS — Codexis Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:02Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CDXS scores 23 out of 100 with letter grade E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -17.85%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 4/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 6/9; Debt/Equity 0.79). Across every pillar the score sits well below the midpoint, so the rating signals weakness broadly rather than in one isolated area. The cash-generation and balance-sheet pillars carry the most concern: negative ROIC and deeply negative FCF yield indicate the business is not currently converting capital into owner returns, and the Altman Z-Score of 0.2 sits in the distress zone of the source's framing. For a prospective investor, the upside case would depend on a turnaround in operating cash flow that the source data does not show; valuation at a $133.6M market cap against a -$44.0M FY 2025 net loss offers no earnings-based anchor. The rating is an analytical signal, not a recommendation, and the risk profile it describes is elevated.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$70.4M	$-41.7M	$-44.0M	N/A	$-23.8M	$50.8M	$40.1M
FY 2024	$59.3M	$-58.5M	$-65.3M	N/A	$-53.7M	$19.3M	$28.9M
FY 2023	$70.1M	$-68.1M	$-76.2M	N/A	$-52.6M	N/A	N/A

Per the SEC financials, the company reported operating and net losses in all three periods, with net margin of -60% per the market data section. Revenue rose from $59.3M in FY 2024 to $70.4M in FY 2025 while the net loss narrowed from $-65.3M to $-44.0M. ROIC is reported at -35%, and the Altman Z-Score is 0.2 with a Piotroski F-Score of 6/9 per the Roarable RQD rating. Debt/Equity is 0.79 per the same section, and FY 2025 cash of $50.8M exceeds reported debt of $40.1M.

Recent Catalysts & News Wire Analysis

Lock-up expiry: A MarketScreener report headlined that certain restricted stock units are subject to a lock-up agreement ending on 22-OCT-2026, flagged as a yellow-light market wire item. This is a dated supply-related watch item.
Shared-control share holding: Stock Titan reported two firms sharing control of 10.8 million CDXS shares held for clients (yellow light).
Insider sale: Investing.com India reported that the CFO sold $8,619 of common stock (yellow light).
Earnings catalyst: A report headlined a Q2 2026 earnings result described as a narrower-than-expected loss with an EPS beat, alongside a buyback announcement (green light, classified as a catalyst). Source data does not provide the underlying figures.
Price action: A report noted shares slipping 2.29% to $1.28 near lower support on retail volume; the current price is $1.22, down 3.17%.
Butterfly Supply-Chain Graph: Supply chain marked NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the company's specific products, customers, and revenue drivers behind the $70.4M FY 2025 revenue?
What do the Q2 2026 earnings figures and the buyback size actually show, given the source data lacks the underlying numbers?
What is the scale of the 22-OCT-2026 lock-up relative to shares outstanding, and what is the company's cash runway given FY 2025 FCF of $-23.8M?
What are the FY 2023 cash and debt balances, which are listed as N/A?
What is the basis for the Congressional PTR cluster flow and Form 4 activity cited in the RQD insider pillar, given the holders section is NONE?

CDXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Codexis Inc. (CDXS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CDXS Debate Forum (3) ↓

🟡 MARKET WIRE Simply Wall St • 12h ago

Codexis (NasdaqGS:CDXS) Stock Forecast & Analyst Predictions

Simply Wall St report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE marketscreener.com • 15h ago

Certain Restricted Stock Units of Codexis, Inc. are subject to a Lock-Up Agreement Ending on 22-OCT-2026.

marketscreener.com report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

Two firms report shared control of 10.8 million Codexis (CDXS) shares held for clients.

Stock Titan report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 21h ago

Codexis CFO Georgia Erbez sells $8,619 of common stock By Investing.com

Investing.com India report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Codexis (CDXS) Slips 2.29% to $1.28 as Shares Hover Near Lower Support - Retail Volume

https://www.siam.in/ report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

CDXS Q2 2026 Earnings: Narrower-Than-Expected Loss as Codexis Tops EPS Estimate - Buyback Announcement Report

https://www.dars.gov.et/ report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Codexis (CDXS) Holds Near $1.30 as Modest Gain Tests Resistance - Wave Truncation

https://www.siam.in/ report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

CDXS Q2 2026 Earnings: Narrower-Than-Expected Loss Per Share Fails to Lift the Stock - Profit Guidance Range

https://www.dars.gov.et/ report covering Codexis Inc. (CDXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CDXS Bull vs. Bear Conversation Board — What's Your Call at $1.19?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CDXS 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.07 (-12.3%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CDXS (E • RQD 23/100) a Buy at $1.22?

Welcome to the CDXS (Codexis Inc.) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Major Chemicals. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.94 (-23.0%)

Spot @ $1.22

Pump the brakes on CDXS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CDXS, but look at what you are paying: current EV/EBITDA multiples with 86.7% gross margins. Unless Codexis Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.54 (+26.2%)

Spot @ $1.22

CDXS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CDXS, the market is fixating on short-term headline noise in Major Chemicals and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $0.96 - $2.98), any beat on forward guidance forces shorts and underweight funds to chase.